Pegfilgrastim shows safety and efficacy similar to filgrastim in patients undergoing autologous stem cell transplantation for hematologic malignancies

Journal of Supportive Oncology

Volumn 3, Issue 2 SUPPL. 1, 2005, Pages 70-71

  Neumeister, Peter ^a   Holub, Robert ^a   Staber, Phillipe B ^a   Linkesch, Werner ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

APLASIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE PAIN; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NEUTROPENIA; NEUTROPHIL; POSTOPERATIVE INFECTION; RETROSPECTIVE STUDY; SINGLE DRUG DOSE;

EID: 15944362184     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (2)

1. Neumeister P, Holub R, Staber PB, Linkesch W. Pegfilgrastim shows safety and efficacy similar to filgrastim in patients undergoing autologous stem cell transplantation for hematological malignancies. Poster presented at the 46th Annual Meeting of the American Society of Hematology; December 4-7, 2004; San Diego, Calif. Abstract 1156.
2. Jagasia MH, Greer J, Kassim A, et al. Pegylated filgrastim (PF) after high dose chemotherapy (HDC) and autologous stem cell transplant (ASCT). Poster presented at the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 6639.